[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2159734T3 - Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. - Google Patents

Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Info

Publication number
ES2159734T3
ES2159734T3 ES96914621T ES96914621T ES2159734T3 ES 2159734 T3 ES2159734 T3 ES 2159734T3 ES 96914621 T ES96914621 T ES 96914621T ES 96914621 T ES96914621 T ES 96914621T ES 2159734 T3 ES2159734 T3 ES 2159734T3
Authority
ES
Spain
Prior art keywords
represented
derivatives
heteroarilalquenilic
cyclopentan
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914621T
Other languages
English (en)
Inventor
Robert M Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2159734T3 publication Critical patent/ES2159734T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE DERIVADOS DE PROSTAGLANDINAS DE TIPO F COMO HIPOTENSORES OCULARES. LOS DERIVADOS DE PGF UTILIZADOS DE ACUERDO CON LA INVENCION ESTAN REPRESENTADOS POR LA FORMULA (I), EN QUE LAS UNIONES REPRESENTADAS POR LINEAS ONDULADAS INDICAN CONFIGURACION TANTO ALFA AL} COMO BETA BE}; LOS SEGMENTOS SOMBREADOS INDICAN CONFIGURACION AL}; LOS TRIANGULOS SOLIDOS SE UTILIZAN PARA INDICAR CONFIGURACION BE}, LOS ENLACES REPRESENTADOS CON LINEA DE PUNTOS REPRESENTAN UN DOBLE ENLACE O UN ENLACE SIMPLE, R ES UN RADICAL HETEROARILO SUSTITUIDO, R SUP,1} ES HIDROGENO O UN RADICAL ALQUILO INFERIOR QUE POSEE HASTA SEIS ATOMOS DE CARBONO, X SE SELECCIONA DEL GRUPO FORMADO POR REPRESENTA DOS RADICALES HIDROGENO. CIERTOS COMPUESTOS REPRESENTADOS POR LA FORMULA (I) CONSTITUYEN OTRO ASPECTO DE LA PRESENTE INVENCION.
ES96914621T 1995-05-18 1996-05-14 Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. Expired - Lifetime ES2159734T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44399295A 1995-05-18 1995-05-18

Publications (1)

Publication Number Publication Date
ES2159734T3 true ES2159734T3 (es) 2001-10-16

Family

ID=23763030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914621T Expired - Lifetime ES2159734T3 (es) 1995-05-18 1996-05-14 Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Country Status (7)

Country Link
EP (1) EP0825980B1 (es)
JP (1) JPH11505802A (es)
AU (1) AU693698B2 (es)
CA (1) CA2221110C (es)
DE (1) DE69613693T2 (es)
ES (1) ES2159734T3 (es)
WO (1) WO1996036599A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1998021180A1 (en) 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
AU6545498A (en) 1997-03-07 1998-09-22 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
CN1350521A (zh) 1999-03-05 2002-05-22 宝洁公司 C16不饱和的fp选择性前列腺素类似物
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
CA2466517A1 (en) 2001-11-05 2003-05-15 Allergan, Inc. .omega.-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
AU2007261034B2 (en) * 2006-06-20 2012-09-13 Allergan, Inc. Therapeutic compounds
ES2752028T3 (es) 2012-10-26 2020-04-02 Forsight Vision5 Inc Sistema oftálmico para la liberación sostenida del fármaco en el ojo
CN105073153B (zh) 2013-03-15 2018-10-30 阿勒根公司 含有前列腺胺的眼内植入物
KR20150141972A (ko) * 2013-04-12 2015-12-21 알레간 인코포레이티드 지방 감소를 위한 비마토프로스트, 비마토프로스트 유사체, 프로스타미드 및 프로스타글란딘의 서방출
US9353079B2 (en) * 2013-12-13 2016-05-31 Allergan, Inc. Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
MX2017013819A (es) 2015-04-30 2018-02-21 Allergan Inc Metodos para la reduccion de grasa.
US10765629B2 (en) 2017-07-25 2020-09-08 Allergan, Inc. Solid complex, preparations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy

Also Published As

Publication number Publication date
AU5792496A (en) 1996-11-29
EP0825980A1 (en) 1998-03-04
JPH11505802A (ja) 1999-05-25
AU693698B2 (en) 1998-07-02
CA2221110A1 (en) 1996-11-21
DE69613693D1 (de) 2001-08-09
EP0825980B1 (en) 2001-07-04
DE69613693T2 (de) 2002-05-16
CA2221110C (en) 2009-08-04
WO1996036599A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
ES2159734T3 (es) Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2157424T3 (es) Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
ES2031841T3 (es) Un procedimiento para la preparacion de derivados de 1,1-dioxido de 2-aminoalquil-1,2-benzoisotiazol-3-(2h)ona.
ES2161290T3 (es) Derivados de quinazolina.
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
ES2117249T3 (es) Derivados de 2,6-diaminopurina.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
PT92821A (pt) Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa
ES2072263T3 (es) Derivados de 4-aminopiridina.
FR2361892A1 (fr) Esters et amides des acides pyrimido(4,5-b)quinolein-4(3h)-one-2-carboxyliques, en tant qu'agents anti-ulceres
ES2037824T3 (es) Un procedimiento para producir un derivado de acido bifosfonico.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2170956T3 (es) Derivados 2-alquenilicos de acido ciclopentan(en)oico como agentes terapeuticos en el tratamiento de hipertension ocular.
ES2032752T3 (es) Procedimiento de preparacion de derivados de la 1-bencenosulfonil-2-oxo-5-alcoxi-pirrolidina.
ES2063465T3 (es) Nuevos derivados n-sustituidos de alfa-mercapto-alquilaminas, su procedimiento de preparacion y los productos intermedios obtenidos, su aplicacion como medicamentos y composiciones que los contienen.
ES2128554T3 (es) Nuevos derivados del acido glutamico, procedimiento para su preparacion y su utilizacion como medicamentos para el aumento de la memoria y aprendizaje.
ES2161936T3 (es) Benzoilguanidinas fluoradas.
ES2179857T3 (es) Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion.
ES2062407T3 (es) Compuestos de 2-hidroxi-3-fenoxipropilamino.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 825980

Country of ref document: ES